Piattaforme di antibody discovery basate su gene editing e AI
| Date | Round | Amount |
|---|---|---|
| May 2026 | Series A Immunocan, a Shanghai antibody discovery platform, closed a RMB 250M (~$35M) Series A led by Vivo Capital, with Gold Mine MFO and follow-on from Kingray and TigerYeah. | $35M |